An immunomodulator
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Paquinimod

Item No. 28443

Technical Information
Formal Name
N,5-diethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide
CAS Number
248282-01-1
Synonyms
  • ABR-25757
Molecular Formula
C21H22N2O3
Formula Weight
Purity
≥98%
A solid
DMF: 20mg/mLDMF:PBS (pH 7.2) (1:5): 0.16mg/mLDMSO: 15mg/mLEthanol: 3mg/mL
λmax
233, 298 nm
SMILES
CCC1=C2C(N(C)C(C(C(N(CC)C3=CC=CC=C3)=O)=C2O)=O)=CC=C1
InChi Code
InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
InChi Key
DIKSYHCCYVYKRO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Paquinimod is an immunomodulator.1,2,3,4 In vivo, paquinimod reduces splenic counts of Ly6ChiCD115+ inflammatory monocytes and CD11b+CD11c+ dendritic cells in a mouse model of experimental autoimmune encephalomyelitis (EAE).1 Paquinimod (25 mg/kg per day) reduces hepatic fibrosis and accumulation of inflammatory monocytes and neutrophils in the N-IF mouse model of liver fibrosis.2 It delays disease onset and decreases insulitis in non-obese diabetic (NOD) mice.3 Paquinimod (5 and 25 mg/kg) reduces skin thickness, the number of myofibroblasts, and autoantibody production in the tight skin 1 mouse model of systemic sclerosis.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Helmersson, S., Sundstedt, A., Deronic, A., et alAmelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: Reduced priming of proinflammatory effector CD4+ T cells. Am. J. Pathol. 182(5), 1671-1680 (2013).

    2. Fransén Pettersson, N., Deronic, A., Hannibal, T.D., et alThe immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis. PLoS One 13(9), e0203228 (2018).

    3. Tahvili, S., Törngren, M., Holmberg, D., et alPaquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One 13(5), e0196598 (2018).

    4. Stenström, M., Nyhlén, H.C., Törngren, M., et alPaquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J. Dermatol. Sci. 83(1), 52-59 (2016).